+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 11 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the combined use of finerenone and empagliflozin compared to usual care to assess their safety and effectiveness in patients hospitalized with heart failure. This international, randomized, controlled, open-label trial aims to study an early, intensive management approach for heart failure treatment. Participants will be assigned to receive either the combination of oral finerenone plus oral empagliflozin or usual care. The study focuses on treatment during hospitalization and shortly after, comparing these approaches to understand the clinical benefits and risks over a six-month period. During the trial, participants will be monitored for clinical outcomes including serious adverse events and events leading to treatment discontinuation. Researchers will measure heart failure events, symptom changes using the Kansas City Cardiomyopathy Questionnaire, and overall survival up to six months. Safety and efficacy data will be collected throughout the study period ending in November 2027.

Age: 18Years +All GendersPhase 3
140 locations
R

Actively Recruiting

Researchers are evaluating the effectiveness and safety of finerenone compared to a placebo in patients hospitalized with acute decompensated heart failure who have mildly reduced or preserved left ventricular ejection fraction. This international, randomized, double-blind, placebo-controlled Phase 3 trial aims to study how finerenone affects morbidity and mortality in these patients. Participants will be randomly assigned to receive either oral finerenone or a matching placebo. The study is event-driven and will monitor patients for up to approximately 30 months. It includes ongoing evaluation of heart failure events, cardiovascular death, and adverse events related to the study drug. Both groups will be observed throughout this period to compare outcomes. During the trial, participants will undergo regular assessments including monitoring for heart failure events, cardiovascular death, and serious adverse events. The study will also measure changes in symptom scores using the Kansas City Cardiomyopathy Questionnaire at 6 months. Safety and tolerability will be closely tracked, including adverse events leading to discontinuation of the study drug. Participants will be followed for up to 30 months to assess long-term effects.

Age: 18Years +All GendersPhase 3
356 locations
S

Actively Recruiting

Researchers are evaluating finerenone compared to a placebo to assess the effectiveness and safety of treatment in patients with heart failure and reduced ejection fraction HFrEF who cannot tolerate or are not eligible for steroidal mineralocorticoid receptor antagonists sMRA. This international study is a randomized, double-blind, placebo-controlled trial focused on this specific group of heart failure patients. Participants will be randomly assigned to receive either oral finerenone or a matching placebo. The study uses a parallel design and treatment will be monitored for up to about 30 months. During this time, researchers will track cardiovascular events, heart failure events, and any serious or adverse events leading to discontinuation of the study drug. Throughout the study, participants will undergo regular assessments including symptom questionnaires and monitoring for cardiovascular outcomes and safety. The main outcomes include the time to the first cardiovascular death or heart failure event and the number of serious adverse events. The study also tracks changes in symptom scores over six months and overall survival. Participants will be followed closely during treatment and after to understand both efficacy and safety.

Age: 18Years +All GendersPhase 3
176 locations
U

Actively Recruiting

This research aims to evaluate the potential of transferring mitochondria from a womans own adipose stem cells to her oocytes during intracytoplasmic sperm injection ICSI to improve embryo development and increase the success rate for women who have experienced multiple failed IVF attempts. Embryo quality is crucial for successful assisted reproductive technologies, and factors such as age and genetics can affect this. Since oocytes depend heavily on mitochondria for energy, boosting mitochondrial content may enhance embryo quality in patients with repeated IVF failures. In this study, mature sibling oocytes will be randomly divided into two groups. One group will undergo conventional ICSI, while the other group will receive mitochondria transplanted from adipose-derived stem cells together with ICSI called Mito-ICSI. Viable blastocysts from both groups will be biopsied for genetic testing to check for chromosome abnormalities. This randomized, double-blind study compares the outcomes of these two approaches. Participants will provide adipose tissue samples through subcutaneous liposuction and consent to have all embryos frozen and biopsied for genetic testing. Researchers will monitor embryo development rates up to 8 weeks after the procedure and track pregnancy outcomes, such as clinical pregnancy rates, live births, and complications, over up to 24 months. The study involves close monitoring and assessments to evaluate the effects of the mitochondrial transfer on embryo quality and pregnancy success.

Age: 29Years - 39YearsFEMALEPhase Not Applicable
1 location
E

Actively Recruiting

Researchers are investigating adults in Sri Lanka with heart failure with reduced ejection fraction HFrEF to assess how an HFrEF polypill strategy affects the combined rate of cardiovascular death and repeated heart failure hospitalizations compared to usual care. The study evaluates this over at least 12 months of follow-up and includes secondary outcomes such as mortality rates, heart function changes via echocardiogram, and quality of life measures. Participants will be randomly assigned to two groups one receives usual care with guideline-directed medications dispensed at no charge when available, while the other receives a combined polypill containing bisoprolol, losartan, eplerenone, and dapagliflozin in three possible dose strengths. The polypill dose will be adjusted during scheduled visits to reach the highest tolerated dose, aiming for the strongest dose by study end. During the study, participants undergo regular visits at 1, 3, 6, 9, and 12 months and every 3 months thereafter, averaging 18 months total. Researchers will monitor heart function, biomarker levels, quality of life questionnaires, medication adherence, and safety outcomes including adverse events and laboratory measures like potassium and creatinine levels. The study includes detailed assessments to evaluate treatment persistence, dose optimization, and overall health impact over time.

Age: 18Years +All GendersPhase 3
12 locations
G

Actively Recruiting

Researchers are conducting an observational, multicenter, international study to learn about antimicrobial resistance AMR in people with chronic lung diseases CLD worldwide. The study aims to understand how common AMR is in these patients, how it varies by location, and what risk factors contribute to it. This study is non-pharmacological and collects data without adding any new treatments or procedures beyond usual care. Data will be collected at multiple centers during two separate two-week periods each year for five years. Participants include patients of all ages with chronic lung diseases who have had at least one respiratory sample collected within the past year. Clinical, demographic, and microbiological information will be gathered through questionnaires and medical records, all recorded in a secure electronic system. No additional tests or interventions outside routine clinical practice will be performed. Participants will provide informed consent before joining. Throughout the study, researchers will monitor the prevalence of antimicrobial resistance and analyze susceptibility patterns of key resistant pathogens, geographical differences, and risk factors for AMR by reviewing collected clinical and microbiological data. The study will last five years, with data collected periodically and securely maintained to better understand AMRs impact on chronic lung diseases.

All AgesAll Genders
68 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety and tolerability of Empagliflozin, with or without metformin, in patients with Type II Diabetes Mellitus within the Pakistani population. This open-label, prospective, observational, single-arm, multi-center post-marketing surveillance study aims to monitor side effects such as hypoglycemia, dehydration, urinary tract infections, and gastrointestinal symptoms. The study is sponsored by Getz Pharma and includes adults aged 18 to 65 years with uncontrolled diabetes despite oral antidiabetic treatment and lifestyle modifications. Participants will receive Empagliflozin alone or combined with metformin in varying doses. The study includes three follow-up visits after starting therapy the first at 4 to 6 weeks, the second at 12 weeks, and the third at 24 weeks. Laboratory tests such as HbA1c, fasting blood glucose, renal function tests, and urine routine examination will be conducted at reputable clinical labs, with participants receiving discounts for these tests. During the study, participants will be closely monitored for safety and efficacy outcomes over six months from enrollment. Assessments include clinical evaluations and laboratory investigations to track diabetes control and potential side effects. The total study duration is 12 months, with the primary outcomes focusing on safety and tolerability at six months and secondary outcomes on efficacy. Participants health will be carefully observed throughout the follow-up period.

Age: 18Years - 65YearsAll GendersPhase 4
6 locations
S

Actively Recruiting

Researchers are evaluating the effects of the SGLT2 inhibitor dapagliflozin compared to metformin on the annual decline in kidney function, measured by eGFR, in people with Type 2 Diabetes. This Phase 3, randomized, double-blind trial is conducted in primary care and community sites in Australia and tertiary care centers in Sri Lanka. The purpose is to understand which first-line therapy may better prevent kidney decline in this population. After a 4-week active run-in period, participants will be randomly assigned to one of two groups one group will take dapagliflozin 10 mg once daily with placebo metformin tablets, and the other group will take metformin XR 2000 mg once daily with placebo dapagliflozin tablets. Treatment will continue for 2 years under quadruple masking to maintain study integrity. During the study, participants will undergo assessments including kidney function tests eGFR, serum creatinine, urine albumin creatinine ratio, blood sugar measurements HbA1C, fasting glucose, blood pressure monitoring, body weight check, and quality of life evaluations using the EQ-5D-5L. Mental health symptoms such as anxiety and depression will also be measured with the HADS questionnaire. The primary outcome is the rate of eGFR decline over 24 months, with safety and other health indicators monitored throughout the study period.

Age: 18Years +All GendersPhase 3
8 locations
D

Actively Recruiting

Healthy Volunteer

Skin pigmentation, skin phototype, and photodamage are important factors affecting skin cancer risk, appearance of skin diseases, treatment responses, and the accuracy of AI diagnosis in dermatology. However, current classification methods are often subjective and can lead to misclassification, reducing the precision of personalized care. This international multicenter observational study aims to develop and validate AI algorithms that classify these skin characteristics more accurately using a combination of objective measures and clinical assessments. Participants aged 18 years and older from multiple countries will complete questionnaires about their skin and sun exposure. Researchers will capture standardized clinical and dermoscopic images of the upper arm and forearm, and perform skin pigmentation measurements using techniques like colorimetry or spectrophotometry when available. The study combines data from questionnaires, objective measurements, clinical scales, and trained observers to create a reliable reference standard for skin pigmentation, phototype, and photodamage. These data will then be used to train and test deep learning AI models. Participants will provide non-invasive skin images and complete questionnaires without any invasive procedures or collection of personal identifiers. The study will assess how well the AI models classify skin characteristics compared to combined reference methods, focusing on accuracy and agreement measures. External validation will also be performed using independent dermatology image datasets to evaluate model performance across diverse populations. The study aims to improve personalized skin cancer risk assessment, support better dermatology care, and address biases in AI systems related to skin tone. Participation involves minimal risk and secure data handling.

Age: 18Years +All Genders
13 locations
S

Actively Recruiting

Researchers are studying the safety, effectiveness, and how the body processes the investigational drug WAL0921 in adults with various glomerular kidney diseases and proteinuria. These include diabetic nephropathy and rare conditions such as primary focal segmental glomerulosclerosis, treatment-resistant minimal change disease, primary immunoglobulin A nephropathy, and primary membranous nephropathy. This is a Phase 2, randomized, double-blind, placebo-controlled study conducted at multiple centers to evaluate WAL0921 compared to a placebo. Participants will be randomly assigned to receive either the investigational drug WAL0921 or a placebo through an intravenous infusion every two weeks for a total of seven infusions. The study includes a treatment period followed by a 24-week follow-up after the last infusion to monitor participants. The treatments are given in parallel groups to compare their effects and safety. During the study, participants will undergo regular assessments including monitoring for adverse events from the start through Week 36. Researchers will also measure changes in albuminuria, proteinuria, and kidney function markers such as estimated glomerular filtration rate over 24 weeks. These evaluations help determine how the drug affects kidney disease markers and overall safety. The total participation time includes treatment and follow-up periods lasting several months.

Age: 18Years - 75YearsAll GendersPhase 2
50 locations

1-10 of 11

1